---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-105599"
form_type: "8-K"
ticker: "KTTA"
cik: "0001841330"
company_name: "Pasithea Therapeutics Corp."
filed_at: "2025-11-04T23:59:59+00:00"
generated_at: "2026-05-17T00:42:16.345293+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Pasithea activates UAB site for Phase 1/1b PAS-004 NF1 trial; platinum sponsor of symposium

## Summary
- New U.S. clinical site at University of Alabama at Birmingham activated for ongoing Phase 1/1b PAS-004 trial in adult NF1 patients; enrollment starts immediately.
- PAS-004 is a next-generation macrocyclic oral MEK inhibitor being studied for symptomatic, inoperable plexiform neurofibromas.
- Pasithea named Platinum Sponsor of the 2025 NF Caregivers Symposium at UAB on November 8, 2025.
- CEO Tiago Reis Marques highlighted UAB's deep NF1 expertise and commitment to advancing care.

## SEC filing metadata
- accession: 0001213900-25-105599
- form_type: 8-K
- ticker: KTTA
- cik: 0001841330
- company_name: Pasithea Therapeutics Corp.
- filed_at: 2025-11-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1841330/000121390025105599/0001213900-25-105599-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1841330/000121390025105599/ea0263823-8k_pasithea.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-105599
- JSON: https://secwatch.observer/filing/0001213900-25-105599.json
- Plain text: https://secwatch.observer/filing/0001213900-25-105599.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.